Maze Therapeutics (MAZE) Competitors $11.50 -0.36 (-3.04%) As of 07/3/2025 01:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock MAZE vs. ARWR, TWST, RXRX, DNLI, VCEL, KNSA, NAMS, APGE, CGON, and IDYAShould you be buying Maze Therapeutics stock or one of its competitors? The main competitors of Maze Therapeutics include Arrowhead Pharmaceuticals (ARWR), Twist Bioscience (TWST), Recursion Pharmaceuticals (RXRX), Denali Therapeutics (DNLI), Vericel (VCEL), Kiniksa Pharmaceuticals International (KNSA), NewAmsterdam Pharma (NAMS), Apogee Therapeutics (APGE), CG Oncology (CGON), and IDEAYA Biosciences (IDYA). These companies are all part of the "pharmaceutical products" industry. Maze Therapeutics vs. Its Competitors Arrowhead Pharmaceuticals Twist Bioscience Recursion Pharmaceuticals Denali Therapeutics Vericel Kiniksa Pharmaceuticals International NewAmsterdam Pharma Apogee Therapeutics CG Oncology IDEAYA Biosciences Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Maze Therapeutics (NASDAQ:MAZE) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk. Is ARWR or MAZE more profitable? Maze Therapeutics' return on equity of 0.00% beat Arrowhead Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Arrowhead PharmaceuticalsN/A -45.33% -12.49% Maze Therapeutics N/A N/A N/A Do analysts recommend ARWR or MAZE? Arrowhead Pharmaceuticals presently has a consensus target price of $43.71, indicating a potential upside of 160.51%. Maze Therapeutics has a consensus target price of $25.67, indicating a potential upside of 123.19%. Given Arrowhead Pharmaceuticals' higher possible upside, equities research analysts clearly believe Arrowhead Pharmaceuticals is more favorable than Maze Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arrowhead Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75Maze Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40 Do institutionals & insiders believe in ARWR or MAZE? 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 4.3% of Arrowhead Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media favor ARWR or MAZE? In the previous week, Arrowhead Pharmaceuticals and Arrowhead Pharmaceuticals both had 1 articles in the media. Maze Therapeutics' average media sentiment score of 1.67 beat Arrowhead Pharmaceuticals' score of 0.77 indicating that Maze Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maze Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has preferable earnings and valuation, ARWR or MAZE? Maze Therapeutics has lower revenue, but higher earnings than Arrowhead Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArrowhead Pharmaceuticals$545.21M4.25-$599.49M-$1.40-11.99Maze Therapeutics$167.50M3.01$52.23MN/AN/A SummaryArrowhead Pharmaceuticals and Maze Therapeutics tied by winning 6 of the 12 factors compared between the two stocks. Get Maze Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MAZE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MAZE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MAZE vs. The Competition Export to ExcelMetricMaze TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$503.70M$2.89B$5.49B$9.01BDividend YieldN/A2.43%5.38%4.09%P/E RatioN/A21.5627.4220.26Price / Sales3.01245.52407.97121.21Price / Cash77.4741.9536.6357.47Price / Book-1.627.518.085.67Net Income$52.23M-$55.05M$3.16B$248.47M7 Day Performance-5.19%4.59%2.81%3.29%1 Month Performance-17.09%4.86%3.68%5.19%1 Year PerformanceN/A5.82%35.29%21.35% Maze Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MAZEMaze TherapeuticsN/A$11.50-3.0%$25.67+123.2%N/A$503.70M$167.50M0.00121ARWRArrowhead Pharmaceuticals3.9373 of 5 stars$16.08+0.1%$43.71+171.9%-33.1%$2.22B$3.55M-11.49400Positive NewsTWSTTwist Bioscience4.4841 of 5 stars$35.93-2.7%$50.40+40.3%-20.6%$2.21B$312.97M-11.06990Positive NewsRXRXRecursion Pharmaceuticals2.1303 of 5 stars$5.03-6.9%$7.00+39.2%-28.4%$2.20B$58.84M-2.84400Analyst ForecastHigh Trading VolumeDNLIDenali Therapeutics4.535 of 5 stars$14.10-2.7%$33.71+139.1%-31.0%$2.11B$330.53M-5.28430High Trading VolumeVCELVericel2.9292 of 5 stars$41.73+0.2%$61.14+46.5%-7.0%$2.10B$237.22M1,391.46300Positive NewsHigh Trading VolumeKNSAKiniksa Pharmaceuticals International3.6932 of 5 stars$28.04-1.6%$38.80+38.4%+45.8%$2.08B$423.24M-112.16220High Trading VolumeNAMSNewAmsterdam Pharma3.0736 of 5 stars$18.57+0.7%$42.89+131.0%-0.8%$2.07B$45.56M-9.884APGEApogee Therapeutics2.9022 of 5 stars$43.38-1.0%$94.60+118.1%+26.8%$2.02BN/A-12.0591News CoverageAnalyst ForecastInsider TradeHigh Trading VolumeCGONCG Oncology2.4153 of 5 stars$25.95-0.5%$58.67+126.1%-12.8%$1.99B$1.14M-17.1961IDYAIDEAYA Biosciences3.5496 of 5 stars$21.37-4.1%$53.42+150.0%-33.6%$1.95B$7M-5.9580High Trading Volume Related Companies and Tools Related Companies Arrowhead Pharmaceuticals Competitors Twist Bioscience Competitors Recursion Pharmaceuticals Competitors Denali Therapeutics Competitors Vericel Competitors Kiniksa Pharmaceuticals International Competitors NewAmsterdam Pharma Competitors Apogee Therapeutics Competitors CG Oncology Competitors IDEAYA Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MAZE) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maze Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maze Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MAZE Stock Alerts